Table 1. Antimicrobial susceptibility of the two C. difficile ribotype 027 isolates identified in this study.
| Antimicrobial agents | Resistant breakpoint (μg/mL) | MIC (μg/mL)/category |
|
|---|---|---|---|
| PUCD235 | PUCD301 | ||
| Erythromycin | ≥8b | ≥256/R | ≥256/R |
| Ciprofloxacin | ≥8b | 128/R | 64/R |
| Clindamycin | ≥8a | 256/R | 128/R |
| Levofloxacin | ≥8b | 256/R | 128/R |
| Meropenem | ≥16a | 2/S | 2/S |
| Metronidazole | ≥32a | 1/S | 1/S |
| Piperacillin/tazobactam | ≥128/4a | 4/4/S | 4/4/S |
| Rifampicin | ≥4b | ≥256/R | ≥256/R |
| Rifaximin | ≥16b | ≥256/R | ≥256/R |
| Tetracycline | ≥16a | 0.125/S | ≤0.064/S |
| Vancomycin | ≥32b | 2/S | 2/S |
Abbreviations: MIC, minimum inhibitory concentration; S: susceptible; R: resistant.
aBreakpoints per CLSI document M100-S25.
bBreakpoints per Huang et al.49.